To rapidly and accurately identify multiple viruses to the clinical manifestation, and frequency of patients presented with upper respiratory tract infections (URTI) at Evagelismos Hospital in Greece-Athens.
100 samples of nasal swabs from patients presented at the emergency department of our hospital, since March 1st 2009, with URTI symptoms were collected. Patients with chronic obstructive pulmonary disease (COPD) and immumosuppression were excluded. The Clinical Arrays PneumoVir test (Oligonucleotide Microarray) was used for the identification of possible viral pathogens. Statistical analysis was performed in order to correlate the microarray data to the clinical symptoms.
Viral load was identified in 50% of patients presented with URTI symptoms. The identified viruses were H1N1, H3N2, Ifluenza B, RSVB, RSVA, human metapneumovirus, human bocavirus and adenovirus. Statistical analysis revealed that there is a significant correlation between viral load and distinct symptoms as nasal drip, myalgies and wheezing.
Our study showed that microarray analysis of nasal swabs can serve as a good test in order to identify viral pathogens rapidly and accurately. This can help clinicians to make a better decision with respect to proper treatment and clinical outcome of URTI. Our study is in progress, therefore more samples will be considered in order to derive more accurate conclusions.
URTI can be caused by a variety of viruses and by bacteria. Clinical symptoms of URTI are highly variable and should not be considered as the only diagnostic tool for the identification of the pathogen and the administration of proper treatment. Serology and bacterial cultures have been the gold standard methods for the identification of the etiologic agent, however these methods are labour intensive, require a trained personnel and time. Microarray oligonucleotide analysis of nasal swabs give as the opportunity to extensively diagnose multiple virus infections for either every day clinical practise or epidemiological survey.
George Tatsis, No Financial Disclosure Information; No Product/Research Disclosure Information